Figure 5.
ET-1R blockade by macitentan inhibits tumor growth and restores sensitivity to oxaliplatin in CRC-SC xenografts. (a) CC09 cells (5 × 105) were injected s.c. into the flank of nude mice. When tumors were detected, mice were treated with vehicle (CTR), or MAC (30 mg/Kg/oral daily), or OX (0.25 mg/Kg/i.p. once a week), or MAC (30 mg/Kg/oral daily) with OX (0.25 mg/Kg/i.p. once a week) combination for 4 weeks. The comparison of the time course of tumor growth curves by two-way ANOVA with group-by-time interaction for tumor growth was statistically significant (P<0.02). Data points, averages±S.D. The upper panels represented the hematoxylin–eosin staining of transplanted tumor xenografts (scale bar, 50 μm) or the images of tumors from each treatment group. (b) Expression of pp42/44MAPK, p42/44MAPK, pAkt and Akt as evaluated by IB on total extracts from tumors of CC09 xenografts. (c) E-cadherin, N-cadherin, Snail and vimentin, evaluated by IB of total extracts from tumors of CC09 xenografts